Chromone derivatives bearing pyridinium moiety as multi-target-directed ligands against Alzheimer's disease.

Bioorg Chem

Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 14176, Iran; Biomaterials Group, Pharmaceutical Sciences Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran 1417614411, Iran. Electronic address:

Published: May 2021

AI Article Synopsis

Article Abstract

A new serise of 7-hydroxy-chromone derivatives bearing pyridine moiety were synthesized, and evaluated as multifunctional agents against Alzheimer's disease (AD). Most of the compounds were good AChE inhibitors (IC = 9.8-0.71 µM) and showed remarkable BuChE inhibition activity (IC = 1.9-0.006 µM) compared with donepezil as the standard drug (IC = 0.023 and 3.4 µM). Compounds 14 and 10 showed the best inhibitory activity toward AChE (IC = 0.71 µM) and BuChE (IC = 0.006 µM), respectively. The ligand-protein docking simulations and kinetic studies revealed that compound 14 and 10 could bind effectively to the peripheral anionic binding site (PAS) of the AChE and BuChE through mixed-type inhibition. In addition, the most potent compounds showed acceptable neuroprotective activity on HO- and Aβ-induced .neurotoxicity in PC12 cells, more than standard drugs. The compounds could block effectively self- and AChE-induced Aβ aggregation. All the results suggest that compounds 14 and 10 could be considered as promising multi-target-directed ligands against AD.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bioorg.2021.104750DOI Listing

Publication Analysis

Top Keywords

derivatives bearing
8
multi-target-directed ligands
8
alzheimer's disease
8
compounds
5
chromone derivatives
4
bearing pyridinium
4
pyridinium moiety
4
moiety multi-target-directed
4
ligands alzheimer's
4
disease serise
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!